Image of Hematology

Split Viewer

Blood Res 2020; 55(4):

Published online December 31, 2020

https://doi.org/10.5045/br.2020.2020156

© The Korean Society of Hematology

Bone marrow involvement by primary oxalosis

Stefano Fratoni1, Pasquale Niscola2

1Surgical Pathology, Hematopathology Unit, 2Haematology Unit, St. Eugenio Hospital, Rome, Italy

Correspondence to : Pasquale Niscola, M.D., Hematology Unit, St. Eugenio Hospital, ASL Roma 2, Piazzale dell’Umanesimo 10, Rome 00144, Italy E-mail: pniscola@gmail.com

Received: June 29, 2020; Revised: October 23, 2020; Accepted: November 12, 2020

This is an Open Access article distributed unAcute myeloid leukemia, New FDA approvalsder the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Systemic oxalosis is a rare autosomal recessive genetic metabolic disorder with an estimated prevalence of less than 1 case/million individuals/year. Alanine glyoxylate aminotransferase deficiency, leading to the endogenous overproduction of oxalic acid as well as the multisystem deposition of calcium oxalate crystals, including kidneys, cartilage, bone, soft tissues, liver, spleen, retina, peripheral nerves, and heart, whereas their bone marrow (BM) localization is very rarely observed. Chronic renal failure (CRF) and pancytopenia being the main clinical consequences. Herein, we describe the case of a 29-year-old woman with CRF on regular hemodialysis and transfusions. Her past medical history revealed primary hyperoxaluria. Blood count showed pancytopenia. Urinalysis revealed hyperoxaluria at 0.84 mmol/L. BM histopathology revealed extensive deposition of large oxalate needle-like crystals arranged in a radial pattern within bony trabeculae (A), stromal fibrosis (B), striking foreign body giant cell reaction (C), thickened bony trabeculae (A, B), and absent residual hematopoiesis. Marked paratrabecular fibrosis was present trapping giant-cell reaction. In conclusion, Clinicians should be aware of the inclusion of oxalosis in the differential diagnosis of patients with unexplained cytopenia. In this clinical scenario, the histopathology of oxalosis is usually straightforward, confirming BM biopsy as an extremely useful tool for diagnosis.

Article

Image of Hematology

Blood Res 2020; 55(4): 192-192

Published online December 31, 2020 https://doi.org/10.5045/br.2020.2020156

Copyright © The Korean Society of Hematology.

Bone marrow involvement by primary oxalosis

Stefano Fratoni1, Pasquale Niscola2

1Surgical Pathology, Hematopathology Unit, 2Haematology Unit, St. Eugenio Hospital, Rome, Italy

Correspondence to:Pasquale Niscola, M.D., Hematology Unit, St. Eugenio Hospital, ASL Roma 2, Piazzale dell’Umanesimo 10, Rome 00144, Italy E-mail: pniscola@gmail.com

Received: June 29, 2020; Revised: October 23, 2020; Accepted: November 12, 2020

This is an Open Access article distributed unAcute myeloid leukemia, New FDA approvalsder the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Body


Systemic oxalosis is a rare autosomal recessive genetic metabolic disorder with an estimated prevalence of less than 1 case/million individuals/year. Alanine glyoxylate aminotransferase deficiency, leading to the endogenous overproduction of oxalic acid as well as the multisystem deposition of calcium oxalate crystals, including kidneys, cartilage, bone, soft tissues, liver, spleen, retina, peripheral nerves, and heart, whereas their bone marrow (BM) localization is very rarely observed. Chronic renal failure (CRF) and pancytopenia being the main clinical consequences. Herein, we describe the case of a 29-year-old woman with CRF on regular hemodialysis and transfusions. Her past medical history revealed primary hyperoxaluria. Blood count showed pancytopenia. Urinalysis revealed hyperoxaluria at 0.84 mmol/L. BM histopathology revealed extensive deposition of large oxalate needle-like crystals arranged in a radial pattern within bony trabeculae (A), stromal fibrosis (B), striking foreign body giant cell reaction (C), thickened bony trabeculae (A, B), and absent residual hematopoiesis. Marked paratrabecular fibrosis was present trapping giant-cell reaction. In conclusion, Clinicians should be aware of the inclusion of oxalosis in the differential diagnosis of patients with unexplained cytopenia. In this clinical scenario, the histopathology of oxalosis is usually straightforward, confirming BM biopsy as an extremely useful tool for diagnosis.

Blood Res
Volume 59 2024

Stats or Metrics

Share this article on

  • line

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download